Sumitomo Mitsui DS Asset Management Company Ltd Buys 61 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Sumitomo Mitsui DS Asset Management Company Ltd increased its stake in shares of United Therapeutics Co. (NASDAQ:UTHR) by 1.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,892 shares of the biotechnology company’s stock after acquiring an additional 61 shares during the quarter. Sumitomo Mitsui DS Asset Management Company Ltd’s holdings in United Therapeutics were worth $856,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also bought and sold shares of the stock. abrdn plc bought a new position in United Therapeutics during the 4th quarter worth approximately $6,218,000. Greenleaf Trust grew its position in shares of United Therapeutics by 11.5% in the 4th quarter. Greenleaf Trust now owns 1,289 shares of the biotechnology company’s stock worth $283,000 after buying an additional 133 shares during the last quarter. Daiwa Securities Group Inc. grew its position in shares of United Therapeutics by 4.0% in the 4th quarter. Daiwa Securities Group Inc. now owns 3,192 shares of the biotechnology company’s stock worth $702,000 after buying an additional 123 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of United Therapeutics by 163.5% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 21,162 shares of the biotechnology company’s stock worth $4,653,000 after buying an additional 13,130 shares during the last quarter. Finally, Private Client Services LLC bought a new stake in shares of United Therapeutics in the 4th quarter worth approximately $629,000. 94.08% of the stock is currently owned by institutional investors.

United Therapeutics Stock Down 0.4 %

Shares of NASDAQ:UTHR opened at $235.95 on Friday. United Therapeutics Co. has a 12-month low of $204.44 and a 12-month high of $261.54. The stock has a fifty day simple moving average of $233.36 and a two-hundred day simple moving average of $228.79. The company has a current ratio of 4.41, a quick ratio of 4.28 and a debt-to-equity ratio of 0.05. The stock has a market capitalization of $11.10 billion, a price-to-earnings ratio of 11.89 and a beta of 0.52.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, February 21st. The biotechnology company reported $4.36 earnings per share for the quarter, topping the consensus estimate of $4.28 by $0.08. United Therapeutics had a return on equity of 17.72% and a net margin of 42.31%. The firm had revenue of $614.70 million during the quarter, compared to analysts’ expectations of $575.01 million. During the same quarter in the previous year, the business earned $2.67 earnings per share. The company’s revenue was up 25.1% on a year-over-year basis. On average, research analysts anticipate that United Therapeutics Co. will post 23.45 earnings per share for the current fiscal year.

Insider Transactions at United Therapeutics

In other news, CEO Martine A. Rothblatt sold 3,600 shares of the business’s stock in a transaction on Wednesday, April 24th. The stock was sold at an average price of $238.81, for a total value of $859,716.00. Following the completion of the transaction, the chief executive officer now owns 130 shares in the company, valued at $31,045.30. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CEO Martine A. Rothblatt sold 3,600 shares of United Therapeutics stock in a transaction on Wednesday, April 24th. The stock was sold at an average price of $238.81, for a total value of $859,716.00. Following the completion of the sale, the chief executive officer now owns 130 shares of the company’s stock, valued at $31,045.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Nilda Mesa sold 325 shares of United Therapeutics stock in a transaction on Wednesday, March 27th. The stock was sold at an average price of $237.80, for a total value of $77,285.00. Following the completion of the sale, the director now directly owns 5,373 shares of the company’s stock, valued at approximately $1,277,699.40. The disclosure for this sale can be found here. Insiders sold 136,990 shares of company stock worth $32,239,641 over the last quarter. 12.50% of the stock is currently owned by insiders.

Analyst Ratings Changes

UTHR has been the topic of a number of recent analyst reports. Wedbush reiterated an “outperform” rating and issued a $308.00 price objective on shares of United Therapeutics in a research report on Thursday, February 22nd. Leerink Partnrs reiterated an “outperform” rating on shares of United Therapeutics in a research report on Monday, February 5th. The Goldman Sachs Group upgraded United Therapeutics from a “sell” rating to a “neutral” rating and lifted their price objective for the stock from $213.00 to $215.00 in a research report on Monday, February 12th. StockNews.com lowered United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, April 11th. Finally, SVB Leerink began coverage on United Therapeutics in a research note on Monday, February 5th. They issued an “outperform” rating and a $330.00 target price for the company. One equities research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $294.25.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.